Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Pharmaceutical Technology on MSN1d
NHS England to offer Casgevy for sickle cell disease patientsThe UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
CRISPR Therapeutics' stock decline is likely ... CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based ...
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback